Aggregation-Inhibiting scFv-Based Therapies Protect Mice against AAV1/2-Induced A53T-α-Synuclein Overexpression

To date, there is no cure for Parkinson’s disease (PD). There is a pressing need for anti-neurodegenerative therapeutics that can slow or halt PD progression by targeting underlying disease mechanisms. Specifically, preventing the build-up of alpha-synuclein (αSyn) and its aggregated and mutated for...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlichtmann, Benjamin W., Palanisamy, Bharathi N., Malovic, Emir, Nethi, Susheel K., Padhi, Piyush, Hepker, Monica, Wurtz, Joseph, John, Manohar, Ban, Bhupal, Anantharam, Vellareddy, Kanthasamy, Anumantha G., Narasimhan, Balaji, Mallapragada, Surya K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452369/
https://www.ncbi.nlm.nih.gov/pubmed/37627268
http://dx.doi.org/10.3390/biom13081203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452369/
https://www.ncbi.nlm.nih.gov/pubmed/37627268
http://dx.doi.org/10.3390/biom13081203

Ejemplares similares